Simtriyo® (centanafadine) is currently under review by the US Drug Enforcement Administration for scheduling pursuant to the Controlled Substances Act and is not yet commercially available.
Simtriyo® (centanafadine) logo

For kids aged 6+ weighing at least 44 lbs (20 kg), teens, and adults with ADHD

Limitations of Use: Simtriyo is not recommended in patients younger than 6 or weighing less than 20 kg due to risk of weight loss.

Simtriyo is

NOW FDA APPROVED

A new type of treatment for ADHD, Simtriyo is designed to address a wide range of symptoms. See full PRESCRIBING INFORMATION, including BOXED WARNINGS.
Sign up for updates and more information.
Sign up
Read the press release
Get updates about Simtriyo
*Indicates required fields.
https://109450-formsgateway.adobeioruntime.net/api/v1/web/formsgateway/register?brand=centabr&formType=consumer_registration
Submit
Thank you,
You’re all set to receive updates about Simtriyo.
first_name
First name
input
true
Enter your first name.
last_name
Last name
input
true
Enter your last name.
email
Email address
input
true
Enter your email address.
i_am
I am...
checkbox
An adult with ADHD | A caregiver of a kid or teen with ADHD | Other
true
Choose at least one option.
is_over_18
optin

By opting in, I confirm that I am 18 years of age or older and I understand that the information I have provided will be used by Otsuka America Pharmaceutical, Inc. (“Otsuka”) and its contracted third parties to contact me by email, and/or direct mail with relevant information about ADHD, Otsuka products, and/or participation in market research opportunities that may be relevant to me. I will have the ability to opt out from receiving Otsuka communications at any time by calling 1-855-627-7873 or by following the opt-out instruction within the communications.

By submitting this form, you are agreeing to our Terms of Use and Privacy Policy.

true
You must check the box.
0
72